Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Oncol (R Coll Radiol) ; 36(3): 193-199, 2024 03.
Article in English | MEDLINE | ID: mdl-38246850

ABSTRACT

AIMS: We present 7 years of clinical experience with single-agent pembrolizumab immune checkpoint inhibitor immunotherapy in non-small cell lung cancers (NSCLC) from four UK cancer centres. MATERIALS AND METHODS: This multi-institutional retrospective cohort study included 226 metastatic NSCLC patients. Outcomes were number and severity of immune-related adverse events (irAEs), median progression-free survival (mPFS) and median overall survival (mOS). RESULTS: Within our cohort, 119/226 (53%) patients developed irAEs. Of these, 54/119 (45%) experienced irAEs affecting two or more organ systems. The most common irAEs were diarrhoea and rash. The development of an irAE was associated with better mOS (20.7 versus 8.0 months; P < 0.001) and mPFS (12.0 versus 3.9 months; P < 0.001). The development of grade 3/4 toxicities was associated with worse outcomes compared with the development of grade 1/2 toxicities (mOS 6.1 months versus 25.2 months, P < 0.01; mPFS 5.6 months versus 19.3 months, P = 0.01, respectively). Females had a higher proportion of reported grade 3/4 toxicities (13/44 [29.5%] versus 10/74 [13.5%], P = 0.03). Using a multiple Cox regression model, the presence of irAEs was associated with a better overall survival (hazard ratio = 0.42, 95% confidence interval 0.29-0.61; P < 0.01) and better PFS (hazard ratio 0.38, 95% confidence interval 0.27-0.53; P < 0.001). CONCLUSION: In this multicentre retrospective cohort study, the development of at least one irAE was associated with significantly longer mPFS and mOS; however, more severe grade 3 and 4 irAEs were associated with worse outcomes. Delayed-onset irAEs, after the 3-month timepoint, were associated with better clinical outcomes.


Subject(s)
Antibodies, Monoclonal, Humanized , Antineoplastic Agents, Immunological , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Female , Humans , Carcinoma, Non-Small-Cell Lung/pathology , Retrospective Studies , Lung Neoplasms/pathology , Nivolumab/adverse effects , Antineoplastic Agents, Immunological/adverse effects
3.
J Laryngol Otol ; 126(10): 1073-6, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22784795

ABSTRACT

OBJECTIVE: We report the use of triamcinolone injections to correct severe nasal deformity due to sarcoidosis, as an alternative to formal surgical rhinoplasty. CASE REPORT: A 30-year-old woman with a long-standing history of sarcoidosis presented to a tertiary referral rhinology clinic complaining of breathing difficulty and nasal deformity. Flexible nasoendoscopy revealed red nasal plaques typical of nasal sarcoidosis, together with significant widening of the nasal bridge. Triamcinolone, a long-acting corticosteroid, was injected both intralesionally and subcutaneously over the nasal dorsum, at zero, three and eight months, resulting in long-lasting improvement of the nasal shape. CONCLUSION: Sarcoidosis is a non-caseating, granulomatous, epithelioid inflammation. Otorhinolaryngological manifestations occur in approximately 10 per cent of patients; however, there is little published experience of nasal reconstruction in such patients. We describe a quick, simple and relatively cost-effective technique, with little or no co-morbidity, with which to improve the aesthetic and symptomatic outcomes of nasal sarcoidosis.


Subject(s)
Glucocorticoids/administration & dosage , Nose Diseases/drug therapy , Sarcoidosis/drug therapy , Triamcinolone Acetonide/administration & dosage , Humans , Injections, Intralesional , Sarcoidosis/surgery
4.
J Laryngol Otol ; 126(3): 328-30, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22236663

ABSTRACT

OBJECTIVE: We report a novel bilateral suture lateralisation technique that allowed permanent tracheostomy decannulation in a patient with severe paradoxical vocal fold movement. CASE REPORT: A 45-year-old woman presented to the accident and emergency department with worsening shortness of breath. Flexible nasoendoscopy revealed limited vocal fold abduction and an emergency tracheostomy was sited; this was subsequently changed to a long-term Silver Negus tube. Her tracheostomy care was complicated by discomfort and dislodgement. The diagnosis of paradoxical vocal fold movement was only made when the patient presented to our department. Cognitive behaviour therapy and botulinum toxin injection were tried without success. A right vocal fold lateralisation procedure was performed, which enabled temporary tracheostomy decannulation. A left vocal fold lateralisation procedure was subsequently performed and the patient was successfully decannulated, with significant improvement in quality of life. CONCLUSION: Paradoxical vocal fold movement is a rare condition that is most commonly managed by biofeedback sessions, relaxation manoeuvres or botulinum toxin injection. However, in cases similar to ours in which these treatments are unsuccessful, we suggest a 'last resort' technique to manage this rare condition.


Subject(s)
Airway Extubation , Dyspnea/surgery , Laryngeal Diseases/surgery , Suture Techniques , Vocal Cords/physiopathology , Anti-Dyskinesia Agents/therapeutic use , Botulinum Toxins/therapeutic use , Cognitive Behavioral Therapy , Dyspnea/etiology , Endoscopy , Female , Humans , Laryngeal Diseases/physiopathology , Middle Aged , Patient Satisfaction , Quality of Life , Tracheostomy/adverse effects , Tracheostomy/instrumentation , Tracheostomy/psychology , Treatment Outcome , Vocal Cords/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...